Adding the HDAC inhibitor valproic acid to decitabine did not improve outcomes in patients with myelodysplastic syndromes or acute myeloid leukemia.
Hematologic Cancer Targets
Patients who experienced early relapse of multiple myeloma after undergoing autologous stem cell transplantation had worse progression-free and overall survival.
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.
Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.
STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.
Treatment with bortezomib prior to autologous stem cell transplant resulted in superior outcomes in multiple myeloma patients with end-stage renal failure.
In a phase I trial, the oral AKT inhibitor afuresertib demonstrated single-agent activity against hematologic malignancies, specifically multiple myeloma.
A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.
Patients with pediatric BCR-ABL1-like acute lymphoblastic leukemia should be given risk-directed therapy based on minimal residual disease levels, according to a new study.
Ibrutinib substantially increased progression-free survival and overall survival over ofatumumab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to the results of the RESONATE trial.